RT Journal Article
SR Electronic
T1 Genome-wide association study of REM sleep behavior disorder identifies novel loci with distinct polygenic and brain expression effects
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21254232
DO 10.1101/2021.09.08.21254232
A1 Krohn, Lynne
A1 Heilbron, Karl
A1 Blauwendraat, Cornelis
A1 Reynolds, Regina H.
A1 Yu, Eric
A1 Senkevich, Konstantin
A1 Rudakou, Uladzislau
A1 Estiar, Mehrdad A.
A1 Gustavsson, Emil K.
A1 Brolin, Kajsa
A1 Ruskey, Jennifer A.
A1 Freeman, Kathryn
A1 Asayesh, Farnaz
A1 Chia, Ruth
A1 Arnulf, Isabelle
A1 Hu, Michele T.M.
A1 Montplaisir, Jacques Y.
A1 Gagnon, Jean-François
A1 Desautels, Alex
A1 Dauvilliers, Yves
A1 Gigli, Gian Luigi
A1 Valente, Mariarosaria
A1 Janes, Francesco
A1 Bernardini, Andrea
A1 Högl, Birgit
A1 Stefani, Ambra
A1 Ibrahim, Abubaker
A1 Sonka, Karel
A1 Kemlink, David
A1 Oertel, Wolfgang
A1 Janzen, Annette
A1 Plazzi, Giuseppe
A1 Biscarini, Francesco
A1 Antelmi, Elena
A1 Figorilli, Michela
A1 Puligheddu, Monica
A1 Mollenhauer, Brit
A1 Trenkwalder, Claudia
A1 Sixel-Döring, Friederike
A1 De Cock, Valérie Cochen
A1 Monaca, Christelle Charley
A1 Heidbreder, Anna
A1 Ferini-Strambi, Luigi
A1 Dijkstra, Femke
A1 Viaene, Mineke
A1 Abril, Beatriz
A1 Boeve, Bradley F.
A1 ,
A1 Scholz, Sonja W.
A1 Ryten, Mina
A1 Bandres-Ciga, Sara
A1 Noyce, Alastair
A1 Cannon, Paul
A1 Pihlstrøm, Lasse
A1 Nalls, Mike A.
A1 Singleton, Andrew B.
A1 Rouleau, Guy A.
A1 Postuma, Ronald B.
A1 Gan-Or, Ziv
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.08.21254232.abstract
AB Rapid eye movement (REM) sleep behavior disorder (RBD), enactment of dreams during REM sleep, is an early clinical symptom of alpha-synucleinopathies. RBD also defines more severe forms of alpha-synucleinopathies. The genetic background of RBD and its underlying mechanisms are not well understood. Here, we performed the first genome-wide association study of RBD, identifying five RBD risk loci. Expression analyses highlight SNCA-AS1 and SCARB2 differential expression in different brain regions in RBD, with SNCA-AS1 further supported by colocalization analyses. Genetic risk score and other analyses provide further insights into RBD genetics, highlighting RBD as a unique subpopulation that will allow future early intervention.Competing Interest StatementS.W.S. serves on the Scientific Advisory Council of the Lewy Body Dementia Association. S.W.S. is an editorial board member for JAMA Neurology and the Journal of Parkinson's Disease. I.A. was previously consultant for Idorsia pharma, and UCB Pharma. A.D. served on the scientific advisory board for Eisai, UCB, Jazz Pharma, received research support from Jazz Pharma, Flamel Ireland, Canopy Growth, and honoraria from speaking engagements from Eisai and Sunovion. M.A.N.'s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc as a data science fellow. Z.G.O. is supported by the Fonds de recherche du QuebecSante (FRQS) Chercheurs-boursiers award, and is a Parkinson's Disease Canada New Investigator awardee. He received consultancy fees from Ono Therapeutics, Handl Therapeutics, Neuron23, Lysosomal Therapeutics Inc., Bial Biotech Inc., Deerfield, Lighthouse, and Idorsia, all unrelated to the current study. Karl Heilbron, Pierre Fontanillas, and the 23andMe Research Team are employed by and hold stock or stock options in 23andMe, Inc.Funding StatementThis work was financially supported by the Michael J. Fox Foundation, Parkinson's Society Canada, the Canadian Consortium on Neurodegeneration in Aging (CCNA), and the Canada First Research Excellence Fund (CFREF) awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program, and was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000535, as well as the National Institute of Neurological Disorders and Stroke. The Montreal iRBD cohort is supported by the Canadian Institutes of Health Research. J.-F.G. holds a Canada Research Chair on Cognitive Decline in Pathological Aging. We thank the members of the NINDS Neurodegenerative Diseases Research Unit and the NIA Laboratory of Neurogenetic for their collegial support and technical assistance.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided informed consent and participated in the research online, under a protocol approved by the external Association for the Accreditation of Human Research Protection Programs (AAHRPP)-accredited IRB, Ethical & Independent Review Services (E&I Review). The study was approved by the McGill University Health Centre Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics for the iRBD data set are available for download at www.tinyurl.com/iRBDsumStats. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data.